Rapport Therapeutics, Inc. Earnings Per Share (Basic)
Rapport Therapeutics, Inc. (RAPP) reported Earnings Per Share (Basic) of -$1.19 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- Rapport Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$1.19.
- Rapport Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.42.
- Rapport Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.72.
- Rapport Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.71.
- Rapport Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$2.86.
- Rapport Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$3.78.
- Rapport Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$23.10.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.19 10-Q · filed 2026-08-05 | -$1.61 10-Q · filed 2026-08-05 | -$2.33 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.05 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.42 10-Q · filed 2026-05-07 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.83 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.56 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$2.18 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.86 10-K · filed 2026-03-10 |
| 2025-09-30 | -$0.71 10-Q · filed 2025-11-06 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.15 10-Q · filed 2025-11-06 | -$2.72 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.75 10-Q · filed 2026-08-05 | -$1.44 10-Q · filed 2026-08-05 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.68 10-Q · filed 2026-05-07 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.75 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$3.78 10-K · filed 2026-03-10 |
| 2024-09-30 | -$0.50 10-Q · filed 2025-11-06 | -$1.57 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$3.66 10-Q · filed 2025-11-06 | -$5.83 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$1.70 10-Q · filed 2025-08-07 | -$6.42 10-Q · filed 2025-08-07 | -$11.31 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$15.82 derived: net income ÷ weighted average shares · filed 2025-08-07 |
| 2024-03-31 | -$11.07 10-Q · filed 2025-05-08 | -$19.37 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$25.58 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$30.61 derived: net income ÷ weighted average shares · filed 2025-05-08 |
| 2023-12-31 | -$8.00 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$13.81 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$18.44 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$23.10 10-K · filed 2025-03-11 |
| 2023-09-30 | -$5.70 10-Q · filed 2024-11-07 | -$10.18 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$14.72 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$4.45 10-Q · filed 2024-08-08 | -$8.96 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |